- Home
- TCRX vs KRRO Comparison
TCRX vs KRRO Comparison
Compare TCRX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- KRRO
- Stock Information
- Founded
- TCRX 2018
- KRRO 2014
- Country
- TCRX United States
- KRRO United States
- Employees
- TCRX N/A
- KRRO N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- KRRO Health Care
- Exchange
- TCRX Nasdaq
- KRRO Nasdaq
- Market Cap
- TCRX 100.7M
- KRRO 101.4M
- IPO Year
- TCRX 2021
- KRRO 2019
- Fundamental
- Price
- TCRX $1.44
- KRRO $12.35
- Analyst Decision
- TCRX Strong Buy
- KRRO Strong Buy
- Analyst Count
- TCRX 6
- KRRO 7
- Target Price
- TCRX $9.50
- KRRO $85.67
- AVG Volume (30 Days)
- TCRX 470.2K
- KRRO 200.2K
- Earning Date
- TCRX 08-11-2025
- KRRO 08-12-2025
- Dividend Yield
- TCRX N/A
- KRRO N/A
- EPS Growth
- TCRX N/A
- KRRO N/A
- EPS
- TCRX N/A
- KRRO N/A
- Revenue
- TCRX $4,421,000.00
- KRRO $4,821,000.00
- Revenue This Year
- TCRX $159.20
- KRRO $65.08
- Revenue Next Year
- TCRX N/A
- KRRO N/A
- P/E Ratio
- TCRX N/A
- KRRO N/A
- Revenue Growth
- TCRX N/A
- KRRO N/A
- 52 Week Low
- TCRX $1.02
- KRRO $10.29
- 52 Week High
- TCRX $7.89
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- TCRX 44.26
- KRRO 41.55
- Support Level
- TCRX $1.44
- KRRO $11.50
- Resistance Level
- TCRX $1.61
- KRRO $16.86
- Average True Range (ATR)
- TCRX 0.16
- KRRO 1.50
- MACD
- TCRX -0.02
- KRRO 0.01
- Stochastic Oscillator
- TCRX 10.44
- KRRO 31.35
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.